A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slides:



Advertisements
Similar presentations
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Advertisements

Moskowitz CH et al. Proc ASH 2014;Abstract 290.
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Presented By Patrick Wen at 2014 ASCO Annual Meeting
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
Activity and Tolerability of Afatinib (BIBW 2992) and Cetuximab in NSCLC Patients with Acquired Resistance to Erlotinib or Gefitinib Janjigian YY et al.
Viardot A et al. Proc ASH 2014;Abstract 4460.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.
Byrd JC et al. Proc ASCO 2011;Abstract 6508.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
October 9 th, 2015 University of Pennsylvania TIES Cancer Research Network Y3 Face to Face Meeting U24 CA Session 6 User Stories and Pilot Studies.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.
May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.
Presented By Michael Overman at 2016 ASCO Annual Meeting
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
CCO Independent Conference Highlights
A cura di Filippo de Marinis
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
CCO Independent Conference Coverage
CCO Independent Conference Coverage
Reeder CB et al. ASCO 2009; Abstract (Poster)
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Highlights: Myeloma Oral Session
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
Presented By Luca Malorni at 2017 ASCO Annual Meeting
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
New Findings in Hematology: Independent Conference Coverage
Intervista a Lucio Crinò
Patient disposition for the double-blind study period.
Metastatic Renal Cell Carcinoma
PCSK9 Inhibitors and Cardiovascular Outcomes
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Baselga J et al. SABCS 2009;Abstract 45.
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Presentation transcript:

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented By William Tap at 2014 ASCO Annual Meeting

Pigmented Villonodular Synovitis (PVNS) Tenosynovial Giant Cell Tumor (TGCT) Presented By William Tap at 2014 ASCO Annual Meeting

Pigmented Villonodular Synovitis (PVNS) Presented By William Tap at 2014 ASCO Annual Meeting

Slide 4 Presented By William Tap at 2014 ASCO Annual Meeting

Can we help patients (PVNS) with a highly targeted therapy (PLX3397) that blocks the CSF1R pathway in this clonal neoplastic process frequently initiated by a single genetic event? Presented By William Tap at 2014 ASCO Annual Meeting

Study Goals Presented By William Tap at 2014 ASCO Annual Meeting

Study Design Presented By William Tap at 2014 ASCO Annual Meeting

Efficacy Assessments Presented By William Tap at 2014 ASCO Annual Meeting

Tumor Volume Score (TVS) Presented By William Tap at 2014 ASCO Annual Meeting

Patient Disposition Presented By William Tap at 2014 ASCO Annual Meeting

Patient Characteristics: Safety Population (n=23) Presented By William Tap at 2014 ASCO Annual Meeting

Safety: PVNS Expansion Cohort AEs n = 23 Safety Population Presented By William Tap at 2014 ASCO Annual Meeting

Treatment-Related AEs ≥ Grade 3 Presented By William Tap at 2014 ASCO Annual Meeting

Duration of Treatment (DOT), April 2014 data cutoff: Median 256 days (range days) Presented By William Tap at 2014 ASCO Annual Meeting

14 patients evaluable with TVS Presented By William Tap at 2014 ASCO Annual Meeting

Slide 16 Presented By William Tap at 2014 ASCO Annual Meeting

Slide 17 Presented By William Tap at 2014 ASCO Annual Meeting

Slide 18 Presented By William Tap at 2014 ASCO Annual Meeting

Slide 19 Presented By William Tap at 2014 ASCO Annual Meeting

Slide 20 Presented By William Tap at 2014 ASCO Annual Meeting

Slide 21 Presented By William Tap at 2014 ASCO Annual Meeting

Conclusions Presented By William Tap at 2014 ASCO Annual Meeting

Thank You Presented By William Tap at 2014 ASCO Annual Meeting